What is Avinger?
Avinger specializes in the design, manufacturing, and sale of advanced medical devices for treating peripheral artery disease. Their core technology, the lumivascular platform, integrates optical coherence tomography (OCT) visualization with interventional catheters, offering physicians real-time intravascular imaging during procedures. The company's product portfolio includes the Lightbox imaging consoles, Ocelot and Tigereye devices for navigating arterial blockages, and the Pantheris image-guided atherectomy device for precise plaque removal. Avinger is also developing solutions for below-the-knee PAD treatments, aiming to broaden its therapeutic reach. The company markets its solutions to interventional cardiologists, vascular surgeons, and interventional radiologists, primarily in the United States and Germany.
How much funding has Avinger raised?
Avinger has raised a total of $125M across 6 funding rounds:
Debt
$10.5M
Stock Offering
$65M
Debt
$33M
Debt
$10M
Stock Offering
$4.5M
Debt
$2M
Debt (2013): $10.5M, investors not publicly disclosed
Stock Issuance/Offering (2015): $65M, investors not publicly disclosed
Debt (2015): $33M supported by CRG
Debt (2016): $10M featuring CRG LP
Stock Issuance/Offering (2019): $4.5M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Key Investors in Avinger
CRG LP
CRG LP is a global investment firm specializing in credit and select equity investments across the healthcare sector, providing flexible growth capital solutions. They leverage extensive experience to create tailored financial strategies for sustainable growth.
CRG
CRG is a global investment firm focused on enhancing healthcare through flexible growth capital solutions, with a specialization in credit and select equity investments. They offer a dynamic array of financing solutions to partners in the healthcare sector.
PPP
Public-Private Partnership
What's next for Avinger?
The recent major strategic investment positions Avinger to accelerate its commercialization strategies and further develop its pipeline of innovative PAD treatment technologies. With a focus on enhancing physician capabilities through advanced imaging and minimally invasive techniques, the company is poised to capture a larger share of the growing PAD market. Future growth will likely involve expanding its sales and marketing infrastructure, pursuing regulatory approvals in new markets, and continuing research and development for next-generation devices. The enterprise-level funding context suggests a strategic phase focused on scaling operations and solidifying market presence.
See full Avinger company page
